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In Brief
The neurotransmitter GABA is released
upon stimulation of the pain receptor
TRPV1 and engages a non-canonical
signaling pathway that inhibits only
hyperactive TRPV1, leaving homeostatic
pain responses intact.
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Sensitization of the capsaicin receptor TRPV1 is cen-
tral to the initiation of pathological forms of pain, and
multiple signaling cascades are known to enhance
TRPV1 activity under inflammatory conditions. How
might detrimental escalation of TRPV1 activity be
counteracted? Using a genetic-proteomic approach,
we identify the GABAB1 receptor subunit as bona fide
inhibitor of TRPV1 sensitization in the context of
diverse inflammatory settings. We find that the
endogenous GABAB agonist, GABA, is released
from nociceptive nerve terminals, suggesting an
autocrine feedback mechanism limiting TRPV1
sensitization. The effect of GABAB on TRPV1 is inde-
pendent of canonical G protein signaling and rather
relies on close juxtaposition of the GABAB1 receptor
subunit and TRPV1. Activating the GABAB1 receptor
subunit does not attenuate normal functioning of
the capsaicin receptor but exclusively reverts its
sensitized state. Thus, harnessing this mechanism
for anti-pain therapy may prevent adverse effects
associated with currently available TRPV1 blockers.
INTRODUCTION
Pathological forms of pain are usually triggered by injury or
inflammation of peripheral sensory neurons of the pain pathway.
A diverse set of inflammatory stimuli can sensitize nociceptive
neurons to promote pain hypersensitivity. As a consequence, in-
hibition of individual inflammatory pathways as ameans to atten-
uate pain is a problematic approach for drug development, as
parallel signaling cascades are still able to drive pathological,
pain-promoting sensitization (Gold and Gebhart, 2010).
One receptor that has been found to serve as downstream
integrator of many inflammatory pathways and thus holds
great hope for anti-pain therapy is the capsaicin receptor
TRPV1 (Caterina et al., 1997; Tominaga et al., 1998).
Next to its physiological function as a detector of noxious
stimuli, a large body of literature attests to a crucial pathologicalrole for TRPV1. Importantly, inflammatory sensitization leads to
dramatically reduced activation thresholds of TRPV1, producing
hyperalgesia and pain hypersensitivity. Indeed, Trpv1/ ani-
mals completely lack thermal hyperalgesia, confirming TRPV1’s
central role as integrator of disparate inflammatory pathways
(Caterina et al., 2000; Davis et al., 2000).
TRPV1’s central role in pathological forms of pain has sparked
intense efforts to develop TRPV1 antagonists. However, block-
ing TRPV1 activity per se leads to impaired noxious heat
sensation and produces hypothermia, attesting to a role of this
temperature-gated receptor in homeostatic thermoregulation.
Therefore, preventing and counteracting sensitization of the re-
ceptor while leaving basal TRPV1 activity untouched has been
suggested to be amore promising avenue for pain therapy (Szal-
lasi and Sheta, 2012; Vay et al., 2012; Woolf, 2010).
Combining mouse genetics with proteomics, here we report
the identification of the GABAB1 receptor as a modulator of
TRPV1 sensitization.
Canonical GABAB signaling requires GABAB1 and GABAB2
receptor subunits to orchestrate activation of inhibitory G pro-
teins (Gassmann et al., 2004; Jones et al., 1998; Kaupmann
et al., 1998; Kuner et al., 1999; White et al., 1998). Surprisingly,
the GABAB2 subunit is dispensable for mediating inhibition of
TRPV1 sensitization, demonstrating that the underlying mecha-
nism diverges from canonical GABAB receptor signaling.
Collectively, our results establish an endogenous GABA/
GABAB1 feedback mechanism that keeps TRPV1-mediated
pain hypersensitivity in check.
RESULTS
Transgenic Tag-TRPV1 Recapitulates Native TRPV1
Function
Given the complex integrative function of the capsaicin receptor,
we reasoned that analysis of TRPV1 accessory proteins would
shed light on unrecognized modulation of the receptor. There-
fore, we utilized a genetic-biochemical approach to identify
components of TRPV1 protein complexes isolated from native
sensory tissue of transgenic animals.
To achieve efficient and specific biochemical purification of
TRPV1 protein complexes for downstream analysis by mass
spectrometry, we generated mice expressing an affinity-taggedCell 160, 759–770, February 12, 2015 ª2015 Elsevier Inc. 759
Figure 1. Tag-TRPV1 Reproduces Native TRPV1 Expression and
Function
(A) Cartoon depicting Tag-TRPV1.
(B) Western blot of solubilized membrane fractions of DRG derived from WT,
Trpv1/, and Trpv1/;Tag-Trpv1 mice.
(C) Immunostaining of DRG derived from WT and Tag-Trpv1 mice with anti-
Flag (green) and anti-TRPV1 (red) antibodies reveals that Tag-TRPV1 re-
capitulates the expression profile of the native receptor.
(D) Tag-TRPV1 expression rescues capsaicin responses in Trpv1/ mice.
Cultured DRG neurons obtained from WT, Trpv1/, and Trpv1/;Tag-Trpv1
mice were challenged with capsaicin and the proportion of responders as-
sessed by calcium imaging. Error bars represent SEM.
(E) Immunostaining of Tag-TRPV1 (anti-Flag antibody, green) and the pan-
neuronal marker PGP9.5 (red) of corneas derived fromWT and Tag-Trpv1mice
reveals that Tag-TRPV1 protein is transported to peripheral sensory endings.
Scale bars, 50 mm.
See also Figure S1.
760 Cell 160, 759–770, February 12, 2015 ª2015 Elsevier Inc.version of TRPV1 (Tag-TRPV1, Figure 1A). Western blotting of
protein extracts derived from sensory ganglia (dorsal root
ganglia, DRG) of transgenic animals revealed the expected
size of the tagged receptor protein, which is slightly shifted to-
ward higher molecular weight compared to native (untagged)
TRPV1 (Figure 1B).
To assure identification of physiological relevant TRPV1 pro-
tein complex components, we first verified cell-type-specific
expression and functionality of the tagged receptor in BAC trans-
genic animals. Tag-TRPV1 expression recapitulated the native
profile in DRG (Figures 1C, S1A, and S1B). Accordingly, the
tagged receptor rescued capsaicin responses in DRG sensory
neurons derived from transgenic animals crossed onto the
TRPV1 knockout background (Figures 1D and S1C). Importantly,
the Tag did not impair trafficking of TRPV1 to peripheral and
central nerve terminals (Figures 1E and S1D).
Finally, we tested TRPV1-dependent nociceptive behavior.
Whereas we observed normal responses to heat stimuli in a
transgenic mouse line expressing close to physiological levels
of Tag-TRPV1, a second line, expressing high levels of the
tagged receptor (Figure S1E), exhibited significantly reduced
pain thresholds (Figure S1F). These findings not only prove the
functionality of the tagged receptor in vivo but also underscore
TRPV1’s predominance in mediating heat hyperalgesia.
Mass Spectrometry Reveals the GABAB1 Subunit as a
Constituent of TRPV1 Protein Complexes
Next, utilizing the Strep or Flagmoiety of the tagged receptor, we
affinity purified protein complexes extracted from DRG of trans-
genic animals expressing both the tagged and the native form of
the receptor. Wild-type animals devoid of the tagged receptor
served as control.
Mass spectrometry revealed the presence of TRPV2—a TRP
family member previously shown to interact with TRPV1 (Rutter
et al., 2005)—in purified protein complexes, further validating
our approach. The GABAB1 receptor subunit was identified as
one of the most abundant components of native TRPV1 protein
complexes, regardless of Tag-TRPV1 expression level (Figures
2A and S2A and Table S1).
Interestingly, GABAB receptors in the CNS have long been
known to mediate analgesia (Sokal and Chapman, 2003). How-
ever, GABAB mechanisms specifically targeting the peripheral
nociceptive pathway have not been identified. Surprisingly,
GABAB receptors are robustly expressed in peripheral nocicep-
tive neurons (Charles et al., 2001; Towers et al., 2000), suggest-
ing an unrecognized role for GABAB in the pain pathway. We
were able to confirm these results and found that most, if not
all, TRPV1-positive sensory neurons express the GABAB1 sub-
unit (Figure 2B).
We validated the presence of GABAB1 in TRPV1 protein com-
plexes by immunoprecipitation (IP) of Tag-TRPV1 or GABAB1
(Figures 2C and 2D).
To further confirm the close proximity of the two transmem-
brane receptors in their native environment, we carried out prox-
imity ligation assays (PLA). In this assay, a fluorescent signal is
generated when two proteins of interest either physically interact
directly or coexist within close molecular distance (So¨derberg
et al., 2006). We therefore cultured DRG neurons of Tag-Trpv1
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Figure 2. GABAB1 and TRPV1Reside in CommonProtein Complexes
(A) Mass spectrometric analysis and quantification of Flag-affinity-purified
Tag-TRPV1 protein complexes derived from DRG of mice expressing either
high or low levels of Tag-TRPV1. Dot plot shows significantly enriched proteins
as log2 fold ratio (Tag-TRPV1/WT). The analysis reveals specific and robust
enrichment for GABAB1a protein.
(B) Immunostaining of DRG ofWTmice with anti-TRPV1 (red) and anti-GABAB1
(green) antibodies shows co-expression of both receptors in nociceptive
neurons. Scale bar, 50 mm.
(C and D) Immunoprecipitations of solubilized protein extracts derived from
DRG of Tag-Trpv1 or WT control animals using immobilized anti-Flag antisera
(C), anti-GABAB1, or control antisera (D). Western blots are probed with anti-
GABAB1 (bottom) or anti-TRPV1 (top panels in C) or anti-Flag antisera (top
panels in D). GABAB1 only co-elutes from affinity resin in the presence, but not
in the absence, of TRPV1 (bottom right panel in C). Note that DRG neurons
predominantly express the GABAB1a isoform and little or no GABAB1b. Simi-
larly, TRPV1 is specifically enriched in isolatedGABAB1 protein complexes (top
right panel in D). Note that endogenous (untagged) TRPV1 protein is precipi-
tated together with Tag-TRPV1, confirming the biochemical isolation of native
tetrameric TRPV1 protein complexes (top right panel in C).
(E) PLA of dissociated DRG neurons of Tag-Trpv1 andWT animals. Antibodies
against Flag and GABAB1 were used to detect proximity of the two receptors.
PLA signal (red) is only present in cell bodies and neurites derived from
Tag-Trpv1 animals. Scale bar, 25 mm.
(F) BRET assay using Rluc-TRPV1 and GABAB1-YFP fusion proteins in the
presence or absence of GABAB2, showing that TRPV1 and GABAB1 strongly
interact and that GABAB2 competes with TRPV1 for GABAB1 binding. Error
bars represent SEM.
(G) No interaction was detected between Rluc-TRPV1 and GABAB2-YFP. Error
bars represent SEM.
See also Figure S2 and Table S1.mice and wild-type control animals and performed PLA using
anti-Flag and anti-GABAB1 antibodies. A robust PLA signal was
detected in Tag-Trpv1 neurons, but not in WT controls, demon-
strating that a TRPV1-GABAB1 complex is present in intact sen-
sory neurons and their projecting neurites (Figure 2E).
Intriguingly, we were not able to detect the GABAB2 subunit
either by mass spectrometry or by western blotting of TRPV1
protein complexes (Figures S2B and S2C). Similarly, KCTD pro-
teins—found to constitutively interact with the GABAB2 receptor
subunit (Schwenk et al., 2010)—were absent, and only GABAB1
selectively co-purified with TRPV1 complexes.
Additionally, when co-expressing TRPV1, GABAB1, and
GABAB2, lower amounts of GABAB1 protein were detected in
TRPV1 IPs when compared to samples containing TRPV1 and
GABAB1 alone (Figures S2D and S2E). These findings suggested
that TRPV1 and GABAB2 might compete for binding to GABAB1.
To further examine this possibility, we carried out biolumines-
cence resonance energy transfer (BRET) assays (Ayoub and
Pfleger, 2010) and expressed Renilla Luciferase BRET donor
(Rluc-TRPV1) and YFP BRET acceptor (GABAB1-YFP, GABAB2-
YFP, or YFP-TRPV1) fusion proteins in a heterologous cell
expression system. While GABAB BRET probes have been
characterized previously (Adelfinger et al., 2014), we first
confirmed the functionality of the TRPV1 BRET probes (Figures
S2F and S2G).
The BRET assay confirmed close association of TRPV1 and
GABAB1 (Figure 2F). Again, no interaction was detectable be-
tween TRPV1 and GABAB2 (Figure 2G). Moreover, similar to
the co-IP experiments (Figures S2D and S2E), co-expressionCell 160, 759–770, February 12, 2015 ª2015 Elsevier Inc. 761
Figure 3. Effect of Baclofen on Native TRPV1 Receptors in Cultured
Sensory Neurons
(A) Electrophysiological recordings of cultured DRG neurons. TRPV1 currents
elicited by capsaicin (500 nM) were not affected by application of 100 mM
baclofen. Rise time (10%–90%, in s): control, 6.5 ± 1.8; Baclofen, 5.8 ± 1.3.
Decay (tau, s): control, 7.6 ± 1.5; Baclofen, 6.8 ± 1.8.
(B) Ca2+ responses (measured as normalized fluorescence ratios) of DRG
neurons stimulated repetitively with capsaicin (100 nM). NGF (100 ng/ml)
sensitized TRPV1 activity resulting in a larger response magnitude. Co-
application of baclofen (100 mM) with NGF resulted in inhibition of TRPV1
sensitization.
(C) Top: simplified cartoon showing the release of inflammatory mediators
during tissue injury. Components of the ‘‘inflammatory soup’’ activate diverse
receptor types, which signal via PKC, PKA, and lipidmodifiers, such as PLC, to
mediate TRPV1 sensitization. Bottom: quantification of averaged fluorescence
762 Cell 160, 759–770, February 12, 2015 ª2015 Elsevier Inc.of GABAB2 interfered with the interaction of Rluc-TRPV1 and
GABAB1-YFP (Figure 2F), shown by the increased amount of
BRET acceptor (GABAB1-YFP) required to reach 50% of the
maximal BRET signal (Figures 2F, S2H, and S2I).
In summary, GABAB1 and TRPV1 form a protein complex that
appears to lack the G protein signaling subunit GABAB2.
GABAB Signaling Counteracts Sensitization of TRPV1
Given GABAB’s established role in modulating KIR3 and CaV
channels (Padgett and Slesinger, 2010), it is conceivable that
GABAB’s known analgesic property could stem in part from
inhibiting TRPV1 activity.
Different to its effect on KIR3 channels (Figure S3A), neither
calcium imaging nor electrophysiological recordings revealed
any influence of the GABAB agonist baclofen on TRPV1 currents
elicited by capsaicin (Figures 3A and S3B). Tachyphylaxis, a
form of rapid TRPV1 desensitization, was also not affected by
baclofen application (Figure S3C).
Under inflammatory conditions, multiple pathways sensitize
TRPV1. Paramount among the different inflammatory sensitizers
is NGF, activating parallel TRKA receptor signaling cas-
cades that converge on the capsaicin receptor to enhance its
sensitivity.
We thus tested whether NGF-mediated TRPV1 sensitization
is modulated by GABAB activation. To this end, we monitored
nociceptive neuron populations for NGF-enhanced TRPV1 activ-
ity using calcium imaging (Bonnington and McNaughton, 2003).
Indeed, pre-incubation of sensory neurons with baclofen (but
not saline) robustly blocked TRPV1 sensitization (Figures 3B,
3C, and S3D).
Apart from the receptor tyrosine kinase TRKA, several G-pro-
tein-coupled receptors (GPCRs) mediate TRPV1 sensitization
(Figure 3C). Notorious in this regard are bradykinin- and seroto-
nin-triggered GPCR cascades (Chuang et al., 2001; Huang et al.,
2006). Strikingly, baclofen was equally effective in inhibiting
TRPV1 sensitization induced by both inflammatory mediators
(Figures 3C, S3E, and S3F).
Given that the initial signaling events controlled by the two
GPCRs are quite different to that of TRKA, these results suggest
that GABAB exerts its effect at a converging point downstream of
the different pathways, potentially at TRPV1 itself. In agreement
with this hypothesis, bypassing upstream inflammatory receptor
signaling by direct pharmacological PKC activation also resulted
in baclofen-reversible TRPV1 sensitization (Figure 3C).
The inflammatory prostaglandin PGE2 mediates TRPV1 sensi-
tization largely via a Gs-coupled/PKA pathway (Gu et al., 2003;
Lopshire and Nicol, 1998; Moriyama et al., 2005). Intriguingly,
baclofen did not inhibit PGE2-mediated TRPV1 sensitization (Fig-
ure 3C). Canonical GABAB-Gi/o coupling would be expected to
effectively counteract Gs-mediated sensitization. In agreementratios as shown in (B). Bar graphs represent the ratios between peaks 6 and 5
(after and before application of inflammatory agents) in the presence or
absence of baclofen (100 mM). Baclofen effectively attenuated TRPV1 sensi-
tization induced by NGF (100 ngl/ml), serotonin (100 mM), bradykinin (10 nM),
and PMA (1 mM), but not by PGE2 (1 mM). Cells treated with vehicle or baclofen
served as a negative control. Error bars represent SEM.
See also Figure S3.
Figure 4. Reversal of TRPV1 Sensitization by GABAB Is Recapitulated in Cellular Expression Systems In Vitro
(A) Calcium responses elicited by 50 nM capsaicin pulses were assessed in TRPV1-HEK293 cells with or without GABAB after incubation with either baclofen
(100 mM), PMA (1 mM), or the combination of PMA+baclofen as indicated. Depicted are representative ratiometric traces from one experiment (n = 50 cells). PMA
promotes PKC-induced TRPV1 sensitization, and baclofen inhibits sensitization only in the presence of GABAB. Error bars represent SEM.
(B) Quantification of experiments shown in (A). PTX (500 ng/ml) did not abrogate the baclofen effect, indicating that Gi/o proteins are not involved in counteracting
TRPV1 sensitization by GABAB.
(C and D) Electrophysiology recordings of oocytes injected with Trpv1, TrkA, andGabaB, following TRPV1 activation with pH 5.8, before and after treatment with
NGF (100 ng/ml) (C) and NGF + baclofen (D).
(E) Quantification of the experiments shown in (C) and (D); sensitization was measured as log2 ratio of capsaicin-elicited steady-state currents before and after
drug treatment. TRPV1 sensitization mediated by NGF is attenuated by baclofen only in the presence of GABAB. Error bars represent SEM.
See also Figure S4.with the apparent absence of the GABAB2 subunit from TRPV1-
GABAB1 complexes, this result further pointed at a potentially un-
recognized GABAB mechanism modulating TRPV1 sensitization
independent of Gi/o signaling.
Non-Canonical GABAB Signaling Counteracts TRPV1
Sensitization
To test directly whether Gi/o protein is involved in mediating the
observed GABAB effect, we pre-incubated sensory neurons
with pertussis toxin (PTX). This selective and potent blocker of
Gi/o proteins did not attenuate baclofen’s effect on TRPV1 sensi-
tization (Figures S4A and S4B), whereas another Gi/o-signaling
cascade present in DRG neurons was effectively inhibited
by PTX (Figures S4C and S4D), thereby serving as a positive
control.
The positive allosteric modulator CPG7930 potentiates
GABAB receptor signaling by binding to the GABAB2 subunit
(Binet et al., 2004). However, inhibition of TRPV1 sensitization
was not significantly enhanced by CPG7930 (Figure S4E) at
concentrations that robustly potentiated GABAB-induced KIR3
currents (Figure S4F), again pointing toward a non-canonical
GABAB pathway.
Next, we tested GABAB’s modulatory effect on TRPV1 sensi-
tization in two heterologous expression systems.We first recapitulated PKC-induced TRPV1 sensitization in a
TRPV1-HEK293 cell line (Siemens et al., 2006). Pre-incubating
the cells with baclofen in the absence of GABAB had no effect
and did not abrogate PKC-mediated TRPV1 sensitization. How-
ever, co-expressing GABAB completely reverted TRPV1 hyper-
activity upon baclofen incubation (Figures 4A and 4B). Similar
to our results in native sensory neurons, PTX did not prevent bac-
lofen to exert inhibition of TRPV1 sensitization (Figure 4B).
Additionally, we reconstituted the NGF sensitization pathway
and expressed the TRKA receptor together with TRPV1 and
GABAB in Xenopus oocytes. Again, we found that baclofen
was able to significantly reduce NGF sensitization in a GABAB-
dependent manner (Figures 4C–4E).
In agreement with the observed close molecular proximity of
the two receptors, these results demonstrate a direct inhibitory
effect of GABAB receptors on TRPV1 sensitization, independent
of classical Gi/o signaling downstream of GABAB2.
GABAB1 Reverts TRPV1 Sensitization Independent of
GABAB2 Signaling
In order to examine the role of the two GABAB receptor subunits
in more detail, we next employed GABAB receptor knockout
mice. A conditional ‘‘floxed’’ GABAB1 mouse line (GabaB1
f/f; Hal-
ler et al., 2004) was crossed to Trpv1-Cremice (Cavanaugh et al.,Cell 160, 759–770, February 12, 2015 ª2015 Elsevier Inc. 763
Figure 5. Surface Expression of GABAB1
in the Absence of GABAB2 Is Sufficient to
Mediate Inhibition of TRPV1 Sensitization
(A) Quantification of capsaicin responses in DRG
neurons from Trpv1-Cre;GabaB1
f/f (GabaB1
/),
GabaB2
/, and WT control mice in the presence
or absence of baclofen (100 mM) following incu-
bation with serotonin (100 mM). Error bars repre-
sent SEM.
(B) Cell surface expression of GABAB1 and
GABAB1-ASAA in the presence or absence of
GABAB2 or TRPV1 was assessed by measuring
the binding of [3H]CGP54626 in intact CHO cells.
Unspecific binding to non-transfected (NT) cells is
set to 1. Error bars represent SEM.
(C) BRET experiment demonstrating that RLuc-
TRPV1 and surface-localized GABAB1-ASAA-YFP
fusion proteins interact. Error bars represent SEM.
(D) Calcium responses in TRPV1-HEK293 cells
transfected with GABAB1 or GABAB1-ASAA after
incubation with either baclofen (100 mM), PMA
(1 mM), or the combination of PMA+baclofen. Error
bars represent SEM.
(E) Quantification of serotonin-sensitized capsa-
icin responses of cultured GabaB2
/ DRG
neurons transfected with a fluorescent reporter
(tomato) in the presence or absence of
GABAB1-ASAA plasmid, incubated with baclofen
(100 mM). Error bars represent SEM.
(F) Representative western blot showing phos-
phorylated (pV1) and total TRPV1 protein (V1)
of HEK cells transfected with control plasmid,
GABAB1+B2, or GABAB1-ASAA alone after treatment
with PMA, PMA+baclofen, or vehicle. Three bio-
logical replicates are loaded onto the gel, but only
one representative lane for eachcondition is shown.
(G) Quantification of (F). Phosphorylated TRPV1
intensity values were normalized to total TRPV1
intensities and expressed as percent of baclofen-
mediated inhibition (PMA+baclofen/PMA). Error
bars represent SEM.
See also Figure S5.2011) to specifically ablate the GABAB1 subunit in TRPV1-posi-
tive sensory neurons (Figure S5A). As expected, inhibition of
TRPV1 sensitization by baclofen was absent in sensory neurons
derived from conditional Trpv1-Cre;GabaB1
f/f mice, attesting to
baclofen’s high specificity and selectivity for the GABAB1 subunit
(Figure 5A). In DRG neurons derived fromGabaB2
/mice (Gass-
mann et al., 2004), the baclofen effect was also abrogated (Fig-764 Cell 160, 759–770, February 12, 2015 ª2015 Elsevier Inc.ure 5A), demonstrating that the GABAB2
subunit is required for mediating TRPV1
modulation, despite its apparent absence
from TRPV1 protein complexes and the
dispensability of Gi/o signaling down-
stream of the GABAB2 subunit.
It is well established that GABAB1 does
not translocate to the cell surface
autonomously, but the GABAB2 subunit
mediates trafficking of the heteromeric
receptor complex by masking an ERretention signal present in the GABAB1 protein (Margeta-Mitrovic
et al., 2000; Pagano et al., 2001). We therefore asked whether
TRPV1 promotes cell surface translocation of GABAB1 indepen-
dent of the GABAB2 subunit. Analyzing cell surface binding of a
GABAB1-specific radioligand [
3H]CGP54626 (Galvez et al.,
2001), we find that TRPV1, different to GABAB2, does not pro-
mote cell surface translocation of GABAB1 (Figure 5B).
Mutating the ER-retention signal encoded by the peptide
sequence ‘‘RSRR’’ to ‘‘ASAA’’ allows surface translocation of
GABAB1 independent of GABAB2 without changing GABAB1’s
signaling capability (Margeta-Mitrovic et al., 2000; Pagano
et al., 2001). Interestingly, this constitutively surface-localized
GABAB1 variant, GABAB1-ASAA (Figure 5B), interacts with TRPV1
similar to its wild-type counterpart (Figure 5C), suggesting that
theGABAB1-TRPV1 protein complex can form at the cell surface.
Expectedly, ER-retained native GABAB1 protein was not in the
position to mediate inhibition of TRPV1 sensitization when ex-
pressed in the absence of the GABAB2 subunit (Figure 5D). Strik-
ingly, surface-localized GABAB1-ASAA alone robustly inhibited
TRPV1 sensitization in HEK293 cells (Figure 5D). Moreover,
GABAB1-ASAA reinstalled baclofen-mediated inhibition of TRPV1
sensitization in GABAB2-deficient sensory neurons (Figures 5E,
S5B, and S5C), demonstrating the ability of GABAB1 to signal
to TRPV1 directly and independently of the GABAB2 subunit.
PKC phosphorylation of TRPV1 sensitizes the receptor (Man-
dadi et al., 2006) and is a convergence point downstream
of NGF, bradykinin, and serotonin signaling. We therefore
examined whether PMA-induced PKC phosphorylation of
TRPV1 is attenuated by GABAB1 signaling. Indeed, we find that
GABAB1-ASAA alone (similar to the native GABAB1+B2 receptor
pair) effectively inhibits PKC phosphorylation of TRPV1 (Figures
5F and 5G).
GABAB Reverts TRPV1 Hypersensitivity in Models of
Inflammatory and Neuropathic Pain
Given the robust cellular effects of GABAB1 on TRPV1 sensitiza-
tion, we next testedwhether these results translate into GABAB1-
mediated inhibition of pain hypersensitivity in animal models.
One nocifensive assay that allows robust measurement of
TRPV1-dependent heat hyperalgesia is the Hargreaves assay.
In this assay, inflammatory stimuli, such as NGF and bradykinin,
decrease the paw withdrawal latency in a TRPV1-dependent
manner (Chuang et al., 2001). Indeed, we observed significant
inhibition of sensitization in baclofen-injected mice compared
to mice that solely received NGF. No effects were detected in
Trpv1/ animals (Figure S6A). To rule out any potential central
effects of baclofen (Sokal andChapman, 2003), we slightlymodi-
fied the testing paradigm and induced inflammatory hyperalge-
sia in both hind paws of the same animal (Figure S6B). We found
robust and dose-dependent inhibition of sensitization only in the
ipsilateral paw that had received baclofen, but not in the contra-
lateral paw (Figures 6A and S6C). Moreover, baclofen’s inhibitory
effect was completely blunted in conditional Trpv1-Cre;GabaB1
f/f
mice (Figure 6B). These findings are in agreement with our
cellular data (Figure 5A) and demonstrate that GABAB1’s benefi-
cial effect on heat hyperalgesia is mediated in peripheral TRPV1-
positive nociceptors in a cell-autonomous fashion, rather than in
higher-order pain-processing CNS areas.
Similarly, GABAB1 receptor activation strongly attenuated se-
rotonin- and bradykinin-triggered heat hyperalgesia but spared
PGE2-triggered heat hyperalgesia (Figures 6A and S6D), an ef-
fect that was not further enhanced by the positive allosteric
modulator CPG7930 that stimulates GABAB2 (Figure S6E).
For therapeutic purposes, it would be beneficial to identify an
intervention that is able to revert pre-existing pain hypersensitiv-ity. Applying baclofen at a time point when NGF had already
sensitized nociceptors reduced heat withdrawal thresholds
(Figure S6F), establishing that GABAB1 activation has the capac-
ity for both prevention and reversal of capsaicin receptor
sensitization.
Given the ability of the GABAB1 subunit to inhibit sensitization
triggered by multiple different inflammatory pathways, we
asked whether it is also effective in attenuating hyperalgesia
as a consequence of intraplantar CFA (complete Freund’s adju-
vant) injection, a widely used model of persistent inflammatory
pain. We found that intraplantar application of baclofen
2 days after inducing CFA-mediated inflammation significantly
reduced heat hyperalgesia compared to vehicle-treated con-
trols (Figure 6C). The beneficial effect of a single dose lasted
for a minimum of 3 hr and had completely ceased 24 hr after
application.
Similar to the cellular assays, our behavior experiments
confirm that GABAB1 activation specifically attenuates hyper-
sensitivity of TRPV1 but did not impinge upon acute responsive-
ness of the receptor to either a heat stimulus, as tested in the
Hargreaves assay (Figure S6G), or assessed bymeasuring acute
capsaicin-induced nocifensive responses (Figure S6H).
GABAB1 and TRPV1 Co-Localize at Peripheral Nerve
Endings
Our data suggest that GABAB1 receptors mediate their anti-hy-
peralgesic effect in the periphery. Consequently, GABAB1 would
be expected to reside in free nerve endings in close proximity to
TRPV1. To elucidate whether the two receptors indeed co-
localize at nociceptor endings, we utilized transgenic GabaB1-
GFP reporter mice (Casanova et al., 2009). Similar to skin, the
cornea is densely innervated by TRPV1-positive sensory fibers,
attesting to strong reactions of the eye to inflammatory insults.
We analyzed both skin and cornea tissue for co-expression of
the two receptors in peripheral nerve endings that project from
DRG and trigeminal (TG) sensory neurons, respectively. Not
only did we find GABAB1 to be present in peripheral nociceptive
fibers, but we also observed substantial co-localization with
TRPV1 in nerve terminals (Figures 6D–6F and S6I–S6K and
Movie S1). In agreement with the close association of TRPV1
and GABAB1 found in Tag-TRPV1-positive DRG neurons (Fig-
ure 2E), 89% of TRPV1-positive corneal fibers co-localize the
two receptors at their terminals (Figure S6L).
GABA Is Released from Peripheral Nociceptors and
Modulates Pain Hypersensitivity
Interestingly, we found that local application of the competitive
GABAB1 receptor antagonist CPG52432 enhanced NGF-medi-
ated TRPV1 sensitization and induced a small but significant
increase in mouse pain behavior compared to NGF alone (Fig-
ure 7A). This result suggested that GABA, the native agonist
of GABAA and GABAB receptors, is endogenously present at
peripheral nerve endings to produce a basal GABAB receptor
tone that regulates TRPV1 sensitivity. Indeed, in blister fluid ob-
tained from human skin and extracted mouse corneal fluid, we
find GABA at concentrations (161 ± 42 nM and 335 ± 54 nM,
respectively) sufficient to inhibit TRPV1 sensitization in cultured
DRG neurons in a GABAB1-dependent manner (Figure 7B).Cell 160, 759–770, February 12, 2015 ª2015 Elsevier Inc. 765
A CB
Basal PGE2BK5HTNGF
-6
-4
-2
0
BacBacBacBaccont ipsi Ctr Ctr Ctr Ctr
***
*** ***
W
ith
dr
aw
al
 la
te
nc
y 
(s)
-5 
-4 
-3 
-2 
-1 
0 
-48 0 1 3 24 
Baclofen
Saline
//
//
//
Baclofen or saline
//
//
**
***
hs
CFA
ED
F
TR
PV
1 G
FP
Tu
J1
TR
PV
1
Tu
J1
G
FP
glabrous skincornea
sk
in
/c
or
ne
a
basement membrane
surface
GFP TRPV1
G
ab
a B
1-
G
FP
 c
o
rn
e
a
x
z
y
y
-6
-4
-2
0
WT
Basal NGF NGF+
Bac
GABAB1-/-
*** ****** n.s.
Basal NGF NGF+
Bac
GabaB1-GFP
Figure 6. GABAB1 Activation in Peripheral Nociceptive Terminals Decreases Thermal Hyperalgesia
(A) Thermal responses were measured using the Hargreaves test. NGF (2 mg/paw), serotonin (5HT, 100 nmol/paw), bradykinin (10 nmol/paw), or PGE2 (1 nmol/
paw) were injected into both mouse hind paws 30 min after unilateral administration of baclofen (Bac, 3 mg/paw) into the ipsilateral paw and vehicle (Ctr) into the
contralateral paw. Bar graph shows the differences in mean paw withdrawal latency upon radiant heat stimulation relative to the basal (non-stimulated) with-
drawal latency. Baclofen decreased thermal hyperalgesia for all inflammatory mediators, except PGE2. Basal withdrawal latencies were measured 24 hr before
the experiment. Error bars represent SEM.
(B) Baclofen does not attenuate NGF-induced thermal hyperalgesia in conditional Trpv1-Cre;GabaB1
f/f mice (GabaB1
/). Error bars represent SEM.
(C) Heat hyperalgesia 2 days after CFA induction is attenuated by baclofen (3 mg/paw) for a minimum of 3 hr when compared to mice that received vehicle only
(saline). Error bars represent SEM.
(D) Cartoon depicting skin or cornea innervation shown in (E) and (F).
(E) Immunostaining of skin and cornea sections obtained from GabaB1-GFP transgenic mice and labeled with antisera for TRPV1 (red), GFP (green), and Tuj1
(blue). Scale bars, 20 mm.
(F) Higher magnification of a single corneal fiber. GABAB1-GFP localizes in TRPV1-positive fibers and is concentrated at the terminal close to the epithelial surface
(demonstrated by orthogonal maximal projections in the x, y, and z dimensions). Scale bar, 10 mm.
See also Figure S6 and Movie S1.
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Figure 7. Peripheral Effects and Localization of GABA and Its
Release from Peripheral Fibers
(A) Withdrawal latencies in mice sensitized with NGF are significantly reduced
by the application of theGABAB1 inhibitor CPG52432 (17 nmol/paw) compared
to mice that received vehicle. Error bars represent SEM.
(B) 200 nM GABA is sufficient to attenuate serotonin sensitization of TRPV1 in
WT but not in Trpv1-Cre;GabaB1
f/f (GabaB1
/) sensory neurons. Error bars
represent SEM.
(C) Cartoon depicting cornea innervation shown in (D); nerve fibers emerge
from the sub-basal nerve plexus and branch out toward the corneal surface.
(D) Sensory fibers innervating the mouse cornea were immune labeled with
antisera decorating GABA (red) and TRPV1 (green). GABA is either distributed
throughout the length of the fibers (left) or concentrated at the terminals close
to the corneal surface (middle) of TRPV1-positive fibers. Although most fibers
contain GABA and TRPV1 conjointly, some fibers harbor GABA in the absence
of TRPV1 (right). Scale bar, 10 mm.
(E) Corneas of WT mice either treated with capsaicin (10 mM) or vehicle
(10 min, 32C) and subsequently prepared for immunostainings using antisera
recognizing GABA and TuJ1. GABA staining was strongly reduced in capsa-
icin-treated corneas compared to control, indicating that TRPV1 activation
stimulates GABA release. Scale bar, 50 mm.
(F) Quantification of (E). Error bars represent SEM.
(G) Model illustrating inhibition of TRPV1 sensitization by GABAB1 receptor
signaling. TRPV1 is sensitized by a multitude of signaling cascades that are
initiated in the context of inflammation. Several cascades converge on PKC, a
kinase shown to robustly mediate TRPV1 sensitization via direct receptor
phosphorylation. Sensitization augments TRPV1 channel activity, which leads
to increased calcium influx and concomitant GABA release to attenuate
TRPV1 sensitization via GABAB1. Activation of this autocrine loop dampens
(or resolves) hyperactivity of TRPV1.
See also Figure S7.Although GABA is well known for its presence in inhibitory
CNS neurons, much less is known about its localization in the
periphery. Using a GABA-specific antibody, we found GABA
localized to the terminal endings of corneal nociceptors, many
of which also express TRPV1 (Figures 7C, 7D, and S7A). Given
that primary afferent nociceptors are glutamatergic, it was unex-
pected to find GABA at their peripheral endings. Presumably, in
these fibers, GABA is stored in vesicles as many of the terminals
also reacted with antibodies for vGAT, the vesicular GABA trans-
porter (Figure S7B). Additionally, DRG and TG sensory neurons
exhibit low Gad2 transcript levels (Figure S7C). Consistently,
we find GABA to be present in DRG and TG neuronal cell bodies
(Figure S7D), albeit the GABA labeling was less pronounced
compared to that observed in TRPV1-positive sensory terminals
(Figure 7D), likely reflecting efficient vesicular transport to distal
terminals.
Given the juxtaposition of GABA vesicles and TRPV1 at
peripheral nerve terminals, we tested whether TRPV1 activation
and subsequent calcium influx would constitute an adequate
stimulus to release GABA. Stimulating isolated corneas with
capsaicin reduces GABA content at the terminals compared to
corneas kept without capsaicin, strongly suggesting that
GABA release has taken place (Figures 7E and 7F). The capsa-
icin-mediated release of GABA is specific to TRPV1 activation,
as it was absent from capsaicin-stimulated corneas of Trpv1/
mice (Figure S7E).
Taken together, these results support a model by which pe-
ripheral GABA limits (and resolves) TRPV1 sensitization via
GABAB1 receptors, directly at the site where painful stimuli are
first encountered (Figure 7G).Cell 160, 759–770, February 12, 2015 ª2015 Elsevier Inc. 767
DISCUSSION
Genetic-Proteomic Dissection of TRPV1 Modulation
Counteracting sensitization of TRPV1—without blocking acute
channel activity—is a promising approach for developing
analgesics. Using infusible peptides mimicking intracellular
TRPV1 domains, it has been demonstrated that interference
with TRPV1 sensitization has beneficial effects in models of in-
flammatory pain (Fischer et al., 2013). However, in contrast to
a multitude of pathways sensitizing TRPV1, endogenous path-
ways inhibiting sensitization have remained elusive.
Combining a genetic-biochemical approach with quantitative
mass spectrometry to probe the molecular environment of
native TRPV1 receptors, we report here the identification of the
GABAB1 receptor as a modulator of TRPV1 sensitization.
Non-Canonical GABAB Signaling Aborts TRPV1
Sensitization
In CNS neurons, most, if not all, GABAB receptor effects are
mediated by coupling to inhibitory Gi/o-type G proteins (Padgett
and Slesinger, 2010). Activating Gi/o-coupled signaling in sen-
sory neurons is able to promote TRPV1 sensitization (Forster
et al., 2009; Loo et al., 2012). Hence, it is difficult to reconcile
the observed inhibitory GABAB effect on TRPV1 sensitization
with a classical Gi/o-coupled signaling cascade.
Multiple lines of evidence suggest that a GABAB1 mechanism
that is independent ofGABAB2 signaling targetsTRPV1hypersen-
sitivity: (1) GABAB2 appears to be absent from GABAB1-TRPV1
complexes; (2) neither PTX nor CPG7930—inhibiting Gi/o activa-
tion or enhancing G protein coupling of GABAB2, respectively—
had any effect on GABAB’s potential to attenuate TRPV1 sensiti-
zation; and (3) plasma-membrane-localized GABAB1 can inhibit
TRPV1 sensitization in the absence of GABAB2.
Ourdata suggest that a ternary complex encompassingTRPV1
and both GABAB subunits is not favored; rather, GABAB2 com-
petes with TRPV1 for GABAB1 interaction. Interestingly, it has
been shown that TRPV1 activation by capsaicin can promote
dissociation of the two GABAB subunits (Laffray et al., 2007).
Thus, it is tempting to speculate that TRPV1 activation promotes
the formation of a surface-localized TRPV1-GABAB1 liaison at the
expense of a heteromeric GABAB1-GABAB2 receptor complex,
thereby priming the nociceptor to guard against sensitization.
GABAB Inhibits Convergent PKC-Mediated TRPV1
Sensitization
How does the GABAB1 receptor mediate its effect on TRPV1?
Given the close proximity of the two proteins, it is possible that
baclofen-induced conformational changes are directly trans-
mitted onto the TRP ion channel to control and regulate its sensi-
tization status. Thiswould be reminiscent of dopamine receptors,
which directly modulate GABAA-type ion channels, independent
of a downstream signaling cascade (Liu et al., 2000).
Alternatively, a putative signaling effector downstream of
GABAB1 may inhibit TRPV1 sensitization. Signaling cascades
downstream of GABAB1 (and independent of GABAB2) have
remained elusive. However, b-arrestin2 has been implicated
to act downstream of GABAB receptors, independent of Gi/o
protein signaling (Lu et al., 2012). b-arrestin2 has also been768 Cell 160, 759–770, February 12, 2015 ª2015 Elsevier Inc.proposed to modulate tachyphylactic TRPV1 responses (Por
et al., 2012), suggesting that this protein could, in principle,
couple GABAB receptors to TRPV1. However, we did not detect
b-arrestin2 in TRPV1-GABAB1 protein complexes, nor did we
find tachyphylactic TRPV1 responses to be modulated by
GABAB receptor activation (Figure S3).
Different to the important functions for b-arrestins in other
GPCR signaling cascades, their role in GABAB-mediated
pathways is less clear (Perroy et al., 2003; Sudo et al., 2012),
suggesting that b-arrestin2 is an unlikely candidate to mediate
the modulatory action of GABAB1 on TRPV1.
Different than the inflammatory pathways initiated by NGF, se-
rotonin, or bradykinin, we find that PGE2-triggered sensitization
of TRPV1 was not inhibited by the GABAB1 receptor. The differ-
ential susceptibility to GABAB1 receptor modulation coincides
with different points of signal convergence on TRPV1; a common
denominator of NGF, serotonin, and bradykinin signaling is the
activation of PLC/PKC pathways that result in sensitization of
the capsaicin receptor (Huang et al., 2006). By triggering PKC
activation directly, we find that this branch of TRPV1 sensitiza-
tion can be inhibited by GABAB1 receptor activity, resulting in
reduced TRPV1 phosphorylation.
In contrast, PGE2 signaling leads to PKA-dependent phos-
phorylation of TRPV1 (Gu et al., 2003; Lopshire and Nicol,
1998; Moriyama et al., 2005), and its sensitizing effect was not
attenuated by GABAB1. Phosphorylating TRPV1 at different sites
may have different functional consequences despite a similar net
effect on sensitization—recent studies demonstrate unique
structural features of TRPV1 with an upper and lower gate that
are independently engaged by different pro-algesic agents to
open and modulate ion channel conductance (Cao et al.,
2013). Thus, it is conceivable that differential phosphorylation
by PKC and PKA mediates different types of TRPV1 gating, the
first of which is susceptible to GABAB1 receptor-mediated inhibi-
tion, whereas the latter is not.
Given that PKC is not the sole mediator of TRPV1 sensitization
utilized by the inflammatory pathways susceptible to GABAB1
inhibition, it is very well possible that other mechanisms are
also targeted and that GABAB provides a broader protection
(or ‘‘shielding’’) against TRPV1 sensitization.
GABAB receptors trigger a surprising range of different cellular
responses. Heteromeric receptor assembly, aswell as the recent
discovery of auxiliary GABAB subunits (Schwenk et al., 2010),
has been proposed to explain contextual signaling diversity
and challenge the classical view of GPCR organization and func-
tion. Our study further corroborates GABAB receptor signaling
complexity and highlights a GABAB2-independent pathway that
mitigates TRPV1-mediated pain hypersensitivity.
Peripheral GABA Regulates Nociceptor Sensitization
It came as a surprise to find not only GABAB receptors but also
their cognate agonist, GABA, localized at peripheral nerve termi-
nals. Classically, vesicular GABA is a hallmark of inhibitory syn-
apses of CNS neurons. Although it is known that the excitatory
transmitter glutamate is present in peripheral nerves, where
it may promote excitability and neurogenic inflammation (Miller
et al., 2011), to our knowledge nothing similar has been reported
for inhibitory transmitters.
Here, we provide evidence that, under physiological condi-
tions, peripheral GABA limits TRPV1-mediated hyperalgesia. It
will be interesting to ascertain whether the peripheral GABA-
GABAB1 feedback on TRPV1 is altered under pathological pain
conditions. Exploiting this endogenous feedback system (e.g.,
by promoting peripheral GABA release or rendering a pharmaco-
logical GABAB1 agonist non-permeable to the blood-brain bar-
rier) may be a valuable route for anti-pain therapy, circumventing
severe adverse effects associated with baclofen’s dominant
CNS activity.
Processing and modulation of painful signals have mainly
been attributed to higher-order brain centers such as the dorsal
spinal cord and beyond. Our model may—after all—not only
inspire new approaches for developing TRPV1-centric pain ther-
apeutics, but it also offers a fresh look at modulation of sensory
input directly at the site of sensory transduction in nerve
terminals, a paradigm that may also be relevant for other so-
matosensory modalities.
EXPERIMENTAL PROCEDURES
Generation of Tag-Trpv1 BAC Transgenic Mice
The SF (Strep-Flag) tag was seamlessly integrated into a mouse BAC clone
(RP23-390G23) encoding the Trvp1 genomic locus, and transgenic mice
were obtained by pronuclear injection.
Behavioral Studies
All animal experiments were in accordance with the local governing bodies.
Thermal pain was assessed by measuring the response latency to a radiant
heat stimulus focused onto the plantar surface of the paw (Hargreaves assay).
Biochemical Protein Complex Purification and Mass Spectrometry
Analysis
Following plasma membrane fractionation of DRG, protein complexes were
affinity isolated using Anti-Flag magnetic beads. Liquid chromatography-tan-
demmass spectrometry (LC-MS/MS) analysis was performed with in-solution
digested affinity purified protein samples on a Q Exactive mass spectrometer
(Thermo Scientific). Label-free quantitation (LFQ) was performed using
MaxQuant Analysis Software.
BRET and PLA Assays
Luminescence and fluorescence signals of COS-1 cells transiently transfected
with plasmids encoding Rluc BRET donor and YFP BRET acceptor fusion pro-
teins were analyzed using an Infinite F500 microplate reader (Tecan).
PLA was performed using Duolink reagents (Sigma) per manufacturer’s
instructions.
Calcium Imaging and Electrophysiological Recordings
For calcium imaging experiments, primary sensory neurons or HEK293 cells
were loaded with the calcium indicators Fura-2 or Cal-520 AM. Electrophysio-
logical recordings were performed using a 700B amplifier and 1440A Analog
Digital Converter (Molecular Devices) in whole-cell voltage clamp configuration.
GABA Measurements
GABA concentrations were determined by LC-MS/MS at Brainsonline
(Groningen).
Statistical Analyses
Data are presented as mean ± SEM. Statistical significance was evaluated
employing Student’s t test for paired comparisons unless indicated otherwise.
p values < 0.05 were considered statistically significant, with *p < 0.05, **p <
0.01, and ***p < 0.001.
Additional Information is available in the Extended Experimental
Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, one table, and one movie and can be found with this article online at
http://dx.doi.org/10.1016/j.cell.2015.01.022.
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